Lower Instruments Sales to Hurt TXG Q3 Earnings, Prelim Sales Down

10x Genomics (TXG) is scheduled to report third-quarter 2024 results on Oct. 29, before market open. In the last reported quarter, the company's adjusted loss per share of 32 cents beat the Zacks Consensus Estimate by 31.9%. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. Let's take a look at how things might have shaped up for GEHC prior to the announcement. Factors at Play 10x Genomics' top line is primarily driven by its two leading platforms — Visium and Zenium — in spatial bio ...